Descrizione del progetto
Un’innovativa piattaforma in-silico per la progettazione di scaffold vascolari bioriassorbibili a rilascio di farmaco
L’aterosclerosi rappresenta un onere significativo per le persone che ne sono affette, in Europa e in tutto il mondo. Di conseguenza, risulta urgente la necessità di soluzioni innovative per migliorare il trattamento e la qualità di vita di questi pazienti. Il progetto InSilc, finanziato dall’UE, sta sviluppando una piattaforma di sperimentazione clinica in-silico per fornire assistenza a ricercatori, cardiologi ed esperti nel settore dell’industria biomedica nella progettazione, nello sviluppo e nella valutazione di scaffold vascolari bioriassorbibili a rilascio di farmaco. Per raggiungere questo obiettivo, il progetto si avvarrà di modelli computazionali avanzati e conoscenze biomediche e biologiche complete al fine di simulare le prestazioni dell’impianto di stent all’interno di anatomie cardiovascolari specifiche per paziente. L’introduzione della piattaforma InSilc consentirà di migliorare significativamente l’approccio terapeutico all’impianto di stent, riducendo i costi diretti e indiretti associati all’assistenza sanitaria.
Obiettivo
The aim of InSilc is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), by building on the comprehensive biological and biomedical knowledge and advanced modelling approaches to simulate their implantation performance in the individual cardiovascular physiology. The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for simulating the drug-eluting BVS mechanical behaviour, the deployment and degradation, the fluid dynamics in the micro- and macroscale, and the myocardial perfusion, for predicting its interaction with the vascular wall in the short- and medium/long term. InSilc goes beyond the design and development of ISCT and lays on the generation of in-silico models for obtaining quick and informed answers to several “What if” scenarios. “Virtual” patients would be given a “virtual” drug-eluting BVS, for observing the performance of the scaffold, assess and quantify the intended effect, with a deeper understanding than normal trials can provide. By integrating the information obtained from different in-silico predictive models, InSilc will: (i) assist in the development, assessment and optimization of the drug-eluting BVS and deliver accurate and reliable information to the Stent Biomedical Industry, (ii) assist the interventional Cardiologists in improving the surgical process of drug-eluting BVS implantation, support them in the clinical assessment and reduce the complications of suboptimal scaffold performance. By introducing computer simulations for establishing the safety and efficacy of drug-eluting BVS, InSilc aims to lower development costs and shorten time-to-market, reduce, refine, and partially replace human clinical trials through a more effective human clinical trials design, reduce the need for animal testing and result in a significant reduction of the associated direct and indirect costs.
Campo scientifico
- medical and health sciencesclinical medicineangiologyvascular diseases
- natural sciencesphysical sciencesclassical mechanicsfluid mechanicsfluid dynamics
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesbasic medicinephysiology
- natural sciencesmathematicsapplied mathematicsstatistics and probability
Programma(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SC1-2017-CNECT-2
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
70013 Irakleio
Grecia